文献速递冠心病血脂与心血管预防

CER-001输注对急性冠脉综合征后冠状动脉粥样硬化的影响:随机临床试验

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该多中心双盲随机试验纳入293例急性冠脉综合征且基线PAV>30%的患者,比较每周10次静脉输注CER-001 3 mg/kg与安慰剂。

要点

  • CER-001 3 mg/kg每周输注10次未显著改善PAV变化。
  • 安慰剂组PAV较基线显著下降0.41%,CER-001组无显著变化。

核心结论

  • 在他汀治疗的急性冠脉综合征且高斑块负荷患者中,CER-001输注未促进冠状动脉粥样硬化消退。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验,纳入293例急性冠脉综合征且基线PAV>30%的患者。
  • 患者随机接受每周静脉输注CER-001 3 mg/kg(n=135)或安慰剂(n=137)共10周,均联合他汀治疗。
  • 主要疗效指标为基线至第78天PAV的名义变化,通过系列血管内超声测量。

主要发现

  • 输注耐受良好,临床和实验室不良事件组间无差异。

临床怎么用

  • 对于他汀治疗的急性冠脉综合征伴高斑块负荷患者,CER-001静脉输注未显示促进斑块消退的获益。

局限性

  • 研究仅纳入基线PAV>30%的急性冠脉综合征患者,结果不能外推至其他人群。
  • 随访至第78天,长期疗效未知。
  • 92.8%患者有可评估影像,部分数据缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: CER-001 is a negatively charged, engineered pre-β high-density lipoprotein (HDL) mimetic containing apolipoprotein A-I and sphingomyelin. Preliminary studies demonstrated favorable effects of CER-001 on cholesterol efflux and vascular inflammation. A post hoc reanalysis of a previously completed study of intravenous infusion of CER-001, 3 mg/k, showed that the intravenous infusion in patients with a high coronary plaque burden promoted regression as assessed by intravascular ultrasonography. OBJECTIVE: To determine the effect of infusing CER-001 on coronary atherosclerosis progression in statin-treated patients. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial evaluating the effect of 10 weekly intravenous infusions of CER-001, 3 mg/kg, (n = 135) or placebo (n = 137) in patients with an acute coronary syndrome (ACS) and baseline percent atheroma volume (PAV) greater than 30% in the proximal segment of an epicardial artery by intravascular ultrasonography. The study included 34 academic and community hospitals in Australia, Hungary, the Netherlands, and the United States in patients with ACS presenting for coronary angiography. Patients were enrolled from August 15, 2015, to November 19, 2016. INTERVENTIONS: Participants were randomized to receive weekly CER-001, 3 mg/kg, or placebo for 10 weeks in addition to statins. MAIN OUTCOMES AND MEASURES: The primary efficacy measure was the nominal change in PAV from baseline to day 78 measured by serial intravascular ultrasonography imaging. The secondary efficacy measures were nominal change in normalized total atheroma volume and percentage of patients demonstrating plaque regression. Safety and tolerability were also evaluated. RESULTS: Among 293 patients (mean [SD] age, 59.8 [9.4] years; 217 men [79.8%] and 261 white race/ethnicity [96.0%]), 86 (29%) had statin prior use prior to the index ACS and 272 (92.8%) had evaluable imaging at follow-up. The placebo and CER-001 groups had similar posttreatment median levels of low-density lipoprotein cholesterol (74 mg/dL vs 79 mg/dL; P = .15) and high-density lipoprotein cholesterol (43 mg/dL vs 44 mg/dL; P = .66). The primary efficacy measure, PAV, decreased 0.41% with placebo (P = .005 compared with baseline), but not with CER-001 (-0.09%; P = .67 compared with baseline; between group differences, 0.32%; P = .15). Similar percentages of patients in the placebo and CER-001 groups demonstrated regression of PAV (57.7% vs 53.3%; P = .49). Infusions were well tolerated, with no differences in clinical and laboratory adverse events observed between treatment groups. CONCLUSIONS AND RELEVANCE: Infusion of CER-001 did not promote regression of coronary atherosclerosis in statin-treated patients with ACS and high plaque burden. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT2484378.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Nicholls SJ, Andrews J, Kastelein JJP, et al. Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 30046828. doi:10.1001/jamacardio.2018.2121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。